Endostatin Inhibits Ischemia-Induced Neovascularization and Increases Ischemic Tissue Loss

Annals of Plastic Surgery

Volumn 52, Issue 5, 2004, Pages 512-518

  Dobryansky, Michael ^a   Galiano, Robert D ^a   Cetrulo Jr , Curtis L ^a   Bhatt, Kirit A ^a   Michaels, Joseph ^a   Ashinofif, Russell ^a   Levine, Jamie P ^a   Gurtner, Geoffrey C ^a,b   Zienowicz, Richard J ^c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c NONE

Author keywords

Angiogenesis; Endostatin; Tissue transfer

Indexed keywords

ANGIOGENESIS INHIBITOR; ENDOSTATIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DORSAL RANDOM CUTANEOUS FLAP; IMMUNOHISTOCHEMISTRY; ISCHEMIA; MICROANALYSIS; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OXYGEN TENSION; PRIORITY JOURNAL; RANDOMIZATION; SKIN FLAP; STATISTICAL SIGNIFICANCE; SURVIVAL; TISSUE INJURY;

ANGIOGENESIS INHIBITORS; ANIMALS; ENDOSTATINS; INJECTIONS, INTRADERMAL; ISCHEMIA; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; NEOVASCULARIZATION, PHYSIOLOGIC; SKIN; SURGICAL FLAPS;

EID: 2042529312     PISSN: 01487043     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.sap.0000123022.98361.c5     Document Type: Article

References (14)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-1186.
2. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000;6:389-395.
3. Liekens S, De Clercq E, Neyts J. Angiogenesis: regulators and clinical applications. Biochem Pharmacol. 2001;61:253-270.
4. O'Reilly MS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88:277-285.
5. Dhanabal M, et al. Endostatin induces endothelial cell apoptosis. J Biol Chem. 1999;274:11721-11726.
6. Kim YM, et al. Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. J Biol Chem. 2002;277:27872-27879.
7. Thomas JP, et al. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol. 2003;21:223-231.
8. Eder JP Jr, et al. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol. 2002;20:3772-3784.
9. Herbst RS, et al. Clinical studies of angiogenesis inhibitors: the University of Texas MD Anderson Center Trial of Human Endostatin. Curr Oncol Rep. 2001;3:131-140.
10. Herbst RS, et al. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol. 2002;20:3804-3814.
11. Kisker O, et al. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res. 2001;61:7669-7674.
12. Mundhenke C, et al. Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin. Clin Cancer Res. 2001;7:3366-3374.
13. Berger AC, et al. The angiogenesis inhibitor, endostatin, does not affect murine cutaneous wound healing. J Surg Res. 2000;91:26-31.
14. Bloch W, et al. The angiogenesis inhibitor endostatin impairs blood vessel maturation during wound healing. FASEB J. 2000;14:2373-2376.